Eyepoint Pharmaceuticals (EYPT) Trading Down 6.2%

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT)’s share price fell 6.2% during trading on Monday . The company traded as low as $1.62 and last traded at $1.67. 567,524 shares were traded during trading, an increase of 41% from the average session volume of 402,456 shares. The stock had previously closed at $1.78.

A number of research firms have commented on EYPT. Zacks Investment Research cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 15th. ValuEngine cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 21st. Finally, HC Wainwright set a $5.00 target price on shares of Eyepoint Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, April 2nd.

The stock has a market cap of $156.41 million, a PE ratio of -2.71 and a beta of 1.95. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.57 and a current ratio of 2.57.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Thursday, March 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. The company had revenue of $2.44 million during the quarter, compared to analysts’ expectations of $0.66 million. Eyepoint Pharmaceuticals had a negative net margin of 1,884.18% and a negative return on equity of 192.19%. On average, equities analysts anticipate that Eyepoint Pharmaceuticals Inc will post -0.32 earnings per share for the current fiscal year.

In related news, Director Douglas Evan Godshall purchased 17,000 shares of the company’s stock in a transaction that occurred on Friday, March 29th. The stock was acquired at an average price of $1.75 per share, with a total value of $29,750.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Nancy Lurker purchased 28,500 shares of the company’s stock in a transaction that occurred on Friday, March 29th. The stock was bought at an average cost of $1.76 per share, with a total value of $50,160.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 50,500 shares of company stock valued at $89,360. 18.91% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in Eyepoint Pharmaceuticals during the fourth quarter worth about $31,000. Bank of New York Mellon Corp raised its stake in Eyepoint Pharmaceuticals by 78.5% during the fourth quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock worth $97,000 after acquiring an additional 22,645 shares in the last quarter. Regal Investment Advisors LLC raised its stake in Eyepoint Pharmaceuticals by 27.3% during the fourth quarter. Regal Investment Advisors LLC now owns 69,950 shares of the company’s stock worth $132,000 after acquiring an additional 15,000 shares in the last quarter. B. Riley Wealth Management Inc. acquired a new position in Eyepoint Pharmaceuticals during the third quarter worth about $164,000. Finally, Tibra Equities Europe Ltd acquired a new position in Eyepoint Pharmaceuticals during the first quarter worth about $202,000. 57.79% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was reported by Modern Readers and is the property of of Modern Readers. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.modernreaders.com/news/2019/04/17/eyepoint-pharmaceuticals-eypt-trading-down-6-2.html.

Eyepoint Pharmaceuticals Company Profile (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

See Also: How is Preferred Stock Different from Common Stock?

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.